CNTG - Centogene N.V.
NASDAQ
->
Healthcare
->
Diagnostics & Research
Rostock,
Germany
Type: Equity
CNTG price evolution
CNTG
| (in millions $) | 30 Jul 2023 | 31 Jan 2023 | 30 Oct 2022 | 30 Jul 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $17.92 | $16.55 | $15.72 | |
| Inventory | $2.13 | $1.82 | $2.15 | |
| Total current assets | $38.91 | $59.83 | $55.34 | |
| Long term investments | ||||
| Property, plant & equipment | $21.61 | $22.16 | $24.28 | |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $71.89 | $92.81 | $90.16 | |
| Current liabilities | ||||
| Accounts payable | $6.95 | $6.32 | $4.76 | |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $26.9 | $24.66 | $23.16 | |
| Long term debt | $53.09 | $53.18 | $37.4 | |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $87.11 | $85.4 | $69.06 | |
| Shareholders' equity | ||||
| Retained earnings | -$18.63 | $4.1 | $17.86 | |
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 | 30 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $17.82 | $48.16 | $41.09 | |
| Short term investments | ||||
| Net receivables | $16.55 | $25.32 | $32.2 | $18.31 |
| Inventory | $1.82 | $3.87 | $11.4 | $1.81 |
| Total current assets | $59.83 | $51.48 | $97.05 | $68.11 |
| Long term investments | ||||
| Property, plant & equipment | $22.16 | $27.05 | $38.71 | $33.31 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $60.64 | $55.33 | ||
| Total investments | ||||
| Total assets | $92.81 | $90.69 | $150.13 | $117.51 |
| Current liabilities | ||||
| Accounts payable | $6.32 | $11.25 | $31.74 | $8.55 |
| Deferred revenue | ||||
| Short long term debt | $0.51 | $0.95 | $1.05 | |
| Total current liabilities | $24.66 | $39.5 | $57.12 | $29 |
| Long term debt | $53.18 | $15.59 | $0.4 | $1.58 |
| Total noncurrent liabilities | $31.11 | $33.14 | ||
| Total debt | ||||
| Total liabilities | $85.4 | $63.19 | $84.35 | $58.59 |
| Shareholders' equity | ||||
| Retained earnings | $4.1 | -$109.3 | -$62.84 | -$40.62 |
| Other shareholder equity | $27.23 | $18.37 | $7.8 | |
| Total shareholder equity | $27.31 | $65.68 | $59.86 | |
| (in millions $) | 30 Jul 2023 | 31 Jan 2023 | 30 Oct 2022 | 30 Jul 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $24.62 | $11.2 | ||
| Cost of revenue | ||||
| Gross Profit | $9.39 | $4.61 | ||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $29.65 | $15.45 | ||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.01 | $0.17 | ||
| Interest expense | -$2.75 | -$2.28 | ||
| Net income | ||||
| Net income | -$24.46 | -$10.35 | ||
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2023 | 31 Jan 2022 | 30 Dec 2020 | 30 Dec 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $128.38 | $48.78 | ||
| Cost of revenue | $81.68 | $26 | ||
| Gross Profit | $46.7 | $22.77 | ||
| Operating activities | ||||
| Research & development | $14.94 | $9.59 | ||
| Selling, general & administrative | $45.24 | $32.41 | ||
| Total operating expenses | $139.54 | $67.37 | ||
| Operating income | -$11.16 | -$18.59 | ||
| Income from continuing operations | ||||
| EBIT | -$11.16 | -$18.59 | ||
| Income tax expense | $0.28 | $0.16 | ||
| Interest expense | -$0.17 | -$1.69 | ||
| Net income | ||||
| Net income | -$21.38 | -$20.86 | ||
| Income (for common shares) | -$21.38 | -$20.86 | ||
| (in millions $) | 30 Jul 2023 | 31 Jan 2023 | 30 Jul 2022 | 30 Mar 2022 |
|---|---|---|---|---|
| Net income | -$6.48 | |||
| Operating activities | ||||
| Depreciation | $3.81 | |||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$9.9 | |||
| Investing activities | ||||
| Capital expenditures | -$0.08 | |||
| Investments | ||||
| Total cash flows from investing | -$2.14 | -$0.73 | -$0.21 | $0.45 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | $20.26 | |||
| Total cash flows from financing | -$5.19 | $46.32 | $31.06 | $34.3 |
| Effect of exchange rate | $0.02 | -$0.96 | ||
| Change in cash and equivalents | -$21.8 | $18.13 | $15.7 | $24.85 |
| (in millions $) | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 | 30 Dec 2019 |
|---|---|---|---|---|
| Net income | -$46.85 | -$21.38 | -$20.86 | |
| Operating activities | ||||
| Depreciation | $17.15 | $7.27 | $4.68 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$21.74 | $8.46 | -$7.78 | |
| Investing activities | ||||
| Capital expenditures | -$2.92 | -$9.89 | -$0.3 | |
| Investments | ||||
| Total cash flows from investing | -$0.73 | -$5.36 | -$16.15 | $14.18 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | -$2.94 | -$7.34 | -$14.4 | |
| Total cash flows from financing | $46.32 | -$3.2 | $14.84 | $25.47 |
| Effect of exchange rate | -$0.96 | -$0.04 | -$0.09 | -$0.09 |
| Change in cash and equivalents | $18.13 | -$30.34 | $7.06 | $31.87 |
News
Fundamentals
| Market cap | $12.85M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 27.87M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.45 |
| Quick ratio | 1.37 |